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Abstract
Non-invasive treatment of injuries and disorders affecting bones and connective tissue is a
significant challenge facing the medical community. A treatment route that has recently been
proposed is nitric oxide (NO) therapy. Nitric oxide plays several roles in physiology with many
conditions lacking adequate levels of NO. As NO is a radical, localized delivery via NO donors is
essential to promoting biological activity. Herein, we review current literature related to
therapeutic NO delivery in the treatment of bone, skin and tendon repair.
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1. Introduction
Musculoskeletal disorders (e.g., arthritis, osteoporosis, and inflammatory bone disease) are a
major health concern in the U.S. due to an aging population and increased occurrence of
sports-related injuries. In addition, roughly 4.4 million people are expected to have one or
more internal fixation devices, of which ~3% will become infected [1, 2]. Osteoporosis,
caused by local or systemic bone loss, occurs most commonly in women after age 40 with
estrogen deficiency due to menopause [3]. Conditions such as osteoporosis lead to bone
fracture and tendon damage. Subsequent wound healing and tendon healing are complex
processes that involve the proliferation and differentiation of bone cells (e.g., osteoblasts)
during development, followed by the production of extracellular matrices in response to
normal and abnormal physiological situations [4, 5]. Moreover, extreme calcium loss and
increases in bone resorption have been linked to several cancers (e.g., bone metastases of
breast and prostate tumors) [3]. While certain drugs (e.g., estrogen and selective estrogen
receptors) are beneficial in inhibiting the formation or activity of osteoclasts, undesirable
side effects limit their long-term use and thus necessitate localized therapeutics. Other
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treatments for musculoskeletal disorders (e.g., injuries to bone, ligaments, and joints) are
based on the use of grafts from existing tissue or implantation of prosthetic devices.
Although fairly successful, invasive orthopedic surgeries still result in poor host tissue
response and microbial infection, particularly for open-fracture boned and joint-revision
surgeries [2, 6]. Thus, molecules that mediate bone formation, resorption and repair, wound
healing, and anti-microbial action at implants have been proposed as candidates for targeted
and localized delivery therapeutics.
Nitric oxide (NO) is an endogenously produced diatomic molecule and that plays multiple
roles in physiological process, including angiogenesis, wound healing, neurotransmission,
smooth muscle relaxation, and inflammation [7]. Nitric oxide's action on physiology is
highly dependent on location, source, and concentration [7, 8]. Nitric oxide is produced in
vivo by NO synthase (NOS), an enzyme that catalyzes the oxidation of a guanidine nitrogen
from L-arginine in the presence of calcium ions, NADH, and tetrahydrobiopterin as co-
factors [7, 8]. Endothelial NOS (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS)
are the three distinct NOS isoforms. [9] Low nanomolar NO concentrations are produced by
eNOS and nNOS to promote vasodilation and neurotransmission, respectively [9]. The
iNOS form is capable of producing micromolar levels of NO, often in response to infection
and inflammation [9]. Nitric oxide has a short half-life (<1 s in the presence of oxygen and
hemoglobin) in vivo, arising from its high reactivity with transition metals, heme-containing
proteins, and thiols [7]. As such, NO's sphere of influence is limited to a few μm [10]. In the
presence of superoxide (O2•−), NO will react to form peroxynitrite (ONOO−), an even
greater oxidant involved in the inflammatory response [11]. Due to the reactive nature of
gaseous NO, chemical strategies for NO storage and release have been developed in an
effort to capture NO's pharmacological potential.
2. Nitric oxide donors
Multiple NO donor types exist with unique NO release triggers and kinetics. N-
diazeniumdiolates (1-amino-substitutied diazen-1-ium-1,2-diolate) and S-nitrosothiols
represent the two most diverse NO donor classes. N-diazeniumdiolates form on secondary
amines under high pressures of NO in the presence of base. Upon proton initiated
degradation (e.g., in water), the NO donor releases two molecules of NO per secondary
amine (Figure 1) [12, 13]. S-nitrosothiols are an endogenous NO carrier but may be
synthesized on free thiol groups upon exposure to a nitrosating agent (e.g., nitrous acid)
[14]. Nitric oxide release of the sulfur-bound NO may be initiated by heat, light, or exposure
to copper ion (Figure 1) [14]. Additionally, transnitrosation may occur resulting in the
transfer of the S-nitrosothiol group to another free thiol group [14]. Both of these NO donors
have the advantage of spontaneously releasing NO without the need of other agents (e.g.,
enzymes). For example, small molecular weight NO donors that have been synthesized and
used in biological studies include (Z)-1-[N-(3-aminopropyl)-N-(n-propyl)amino]diazen-1-
ium-1,2-diolate (PAPA/NO), 1-[N-(aminoethyl)-N-(2-ammonioethyl)amino] diazen-1-
ium-1,2-diolate (DETA/NO), S-nitrosoglutathione (GSNO), and S-nitroso-N-acetyl-
penicillamine (SNAP) [15, 16]. To enhance NO payloads and/or expand the utility of NO
release, macromolecular NO release scaffolds have been developed with similar NO donor
chemistry. Materials spanning xerogels [1, 11, 17], silica nanoparticles [18–20], dendrimers
[21, 22], synthetic polymers [23–25], and electrospun fibers [26] have been reported.
Among the NO donors already used clinically, organic nitrates have been most widely
employed [27], with their use dating to the 1870s [28], While the release of NO from
organic nitrates is invoked without the assistance of enzymes to some extent, the primary
mechanism of NO production is enzymatic (Figure 1) [27]. For example, nitroglycerin, the
most commonly used organic nitrate, primarily “releases” NO upon bioactivation by
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mitochondrial aldehyde dehydrogenase (mtALDH) [29, 30]. Unfortunately, patients often
develop a tolerance to nitroglycerin due in part by inactivation of mtALDH in response to
oxidative stress [31, 32], thus limiting the NO-donating capacity of nitroglycerin, reducing
treatment efficacy and complicating clinical results. Despite these potential shortcomings,
much NO release-related clinical research data is based on nitroglycerin.
Metal nitrosyl compounds represent another class of compounds used to generate NO in
biological studies. Two examples of metal nitrosyls are sodium nitroprusside
(Na2[Fe(CN)5NO], SNP) and potassium nitrosylpentachlororuthenate (K2[Ru(NO)Cl5],
NPR), with SNP being the most common [27, 33]. For 70 years, SNP has been used to
reduce blood pressure in hypertensive emergencies [27]. Metal nitrosyls are capable of
releasing NO enzymatically, non-enzymatically when in the presence of vascular tissue and
reducing agents (e.g., ascorbic acid), or by light irradiation [27, 34, 35]. However, cellular
toxicity is a concern for SNP use due to the liberation of cyanide and the formation of
cytotoxic peroxynitrite upon the release of NO [27]. Structures for the metal nitrosyl
compounds and other NO-releasing materials discussed are provided in Figure 2.
The NO release kinetics and total payloads for common NO donors are shown in Table 1.
While the NO release mechanism for N-diazeniumdiolates is well understood, NO release
for S-nitrosothiols, organic nitrates, and metal nitrosyls are highly dependent on a number of
factors including enzymes, free thiols, and light. Therefore, the NO release kinetics of these
donors vary significantly, particularly in vitro vs. in vivo, and thus are excluded from Table
1.
Based on recent research demonstrating the utility of NO release as an antibacterial and
wound healing promoting agent, the localized delivery of NO using NO donors represents a
promising strategy for reducing implant-associated infections and promoting tissue
regeneration in the orthopedic arena. The risk of systemic toxicity and undesirable side
effects may be mitigated by careful selection of NO donors. Next, we detail the role of NO
in bone formation, resorption, and repair.
3. Nitric oxide delivery to bone
3.1. Roles of NO in bone tissue
Bone is a complex, dynamic, living tissue that undergoes constant remodeling carried out by
osteoblasts and osteoclasts that deposit new bone and remove existing mineralized bone and
organic tissue, respectively [36]. Imbalances in bone turnover result in a variety of medical
conditions. For example, the over-activity of osteoclasts amplifies bone loss in post-
menopausal osteoporosis, while reduced osteoclastic activity is a major contributor to
osteopetrosis, a condition characterized by excess mineralized bone.
Nitric oxide is involved in the cellular processes responsible for bone turnover.
Constitutively generated by eNOS, NO contributes to the proliferation and differentiation of
osteoblasts [37]. When eNOS is specifically targeted for disruption in mice, osteoblasts
cultured from their tissue show inhibited proliferation and decreased activity [37, 38]. Nitric
oxide also plays a pivotal role in osteoclastic activity as decreased NO levels have been
shown to enhance osteoclastogenesis and associated bone resorption [39]. This effect
appears to be biphasic, as high concentrations of NO inhibit cytokines that contribute to
bone resorption whereas low concentrations potentiate their effect.[40] Nitric oxide may
play a part in the multinucleation of osteoclasts as evidenced by elevated NO levels in pre-
osteoclasts prior to cell fusion [41].
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Nitric oxide expression by bone cells is in part regulated by sex hormones such as estrogen.
One such estrogen, 17β-estradiol, promotes apoptosis of osteoclasts by inhibiting bone
resorption [42]. In osteoblasts, exposure to 17β-estradiol upregulates eNOS [43].
Constitutive NO production stimulated by eNOS then promotes proliferation and
differentiation of osteoblasts, resulting in increased bone deposition [44]. Targeted
disruption of eNOS in mice nullifies the beneficial effects of exogenously supplied estrogen,
suggesting that NO is a significant factor in estrogen-promoted bone formation [45]. These
findings have guided research efforts towards NO therapy as a treatment for post-
menopausal osteoporosis when estrogen levels are depressed [46].
The activity of all three NOS isoforms is increased following fracture in humans and rats,
indicating NO is also involved in bone fracture repair [47, 48]. Diwan et al. found that iNOS
levels increased 4 d after fracture, proceeded by a delayed increase in eNOS and nNOS
expression [47]. Rats supplemented with L-NG-nitroarginine methyl ester (L-NAME), a
non-specific NOS inhibitor, experienced inhibited fracture healing as evidenced by a
reduction in the cross-sectional area and failure load of explanted femurs. Evaluating the
role of iNOS specifically in fracture healing through targeted gene deletion illustrated that
femurs from iNOS deficient mice had a decreased total and maximum energy absorption
following fracture, although the biomechanical properties remained unaffected [48].
Mechanical strain at forces lower than those necessary for fracture also stimulates NO
production, ultimately helping bone adapt to its functional needs [49]. As a way to regulate
the constant remodeling necessary for this process, mechanical strain on osteoclast
progenitor cells increases local NO concentrations by upregulating eNOS and consequently
reducing osteoclastic activity [49, 50]. Osteoblasts also respond to strain and shear stress
through the activation of protein kinase by cyclic guanasine monophosphate (cGMP), a
species activated by NO released in response to strain [51]. Bone resorption is also
controlled through suppression of the receptor activator of nuclear factor kappa-B ligand
(RANKL) [52], a member of the tumor necrosis factor family and an essential factor for
osteoclastogenesis. Interestingly, chemically-induced inhibition of nNOS and eNOS in
mechanically strained stromal cells reversed the inhibition of RANKL associated with strain
[53]. Although experiments in eNOS deficient mice demonstrate that alternative pathways
for RANKL inhibition still exist, this suggests that RANKL inhibition is in part mediated by
NO [53].
Taken together, the wide array of bone processes that NO is involved in suggest that
delivery of NO to bone in a controlled and targeted manner may result in new and effective
treatments for fracture repair and conditions caused by imbalances in bone turnover. The
effects of exogenous NO on bone cells are thus described below.
3.2. Effects of exogenous NO on bone cells
3.2.1. Effects of NO on osteoblasts—Endothelial NOS generated by osteoblasts
contributes to their proliferation. It is unsurprising then, that NO supplied exogenously also
stimulates osteoblast growth. Osteoblast-like cells treated with the non-selective NOS
inhibitor, NG-monomethyl-L-arginine (L-NMMA), demonstrated a dose-dependent growth
inhibition that was restored upon treatment with SNP or L-arginine [54]. Using targeted
disruption of the eNOS isoform as opposed to a non-selective inhibitor demonstrated similar
results; mice lacking eNOS showed reduced bone formation and bone volume [37].
Osteoblasts isolated from the femurs of eNOS deficient mice exhibited decreased
proliferation and differentiation as evidenced by reduced alkaline phosphatase activity [37].
When incubated with SNAP (1 μM), cell number and alkaline phosphate activity were
restored to wild-type levels. To determine whether exogenous NO enhanced bone growth
rather than simply restoring it following gene disruption, the same experiment was
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performed on osteoblasts from wild-type mice. Although alkaline phosphatase levels did not
increase, the wild-type osteoblasts grew to increasing numbers when incubated with 1 μM
SNAP [37], demonstrating NO's potential as a therapeutic for bone growth.
Similarly, Otsuka et al. found that incubation of osteoblasts with an unspecified
concentration of DETA/NO had no effect on alkaline phosphatase activity [54]. However, a
3.5-fold increase in osteocalcin, an osteoblast-generated protein that contributes to bone
matrix mineralization was noted over the 12 d incubation period. Consistent with this
observation was an increase in the number of mineralized bone nodules formed from
osteoblasts treated with DETA/NO.
Ultimately, the rate at which NO is released from an NO donor species will significantly
impact the concentration of NO in its localized sphere of influence. Since NO concentration
has a profound effect on cellular activity, the release kinetics (illustrated in Figure 3) from
the NO donor must be considered. Mancini et al. postulated that the slow release of NO
from DETA/NO mimicked the release of NO from eNOS, while release from iNOS was
more accurately modeled by a compound such as SNP that releases NO more rapidly [55].
Cell counts increased when osteoblasts were incubated with 10 μM DETA/NO for 3 d while
they were unaffected at the same concentration of SNP. At elevated NO donor
concentrations (50 μM), DETA/NO still contributed to cell growth while SNP initiated
apoptosis. Larger NO donor concentrations (100 μM) reversed the observed proliferative
effect, while the trend of SNP-induced killing continued. In addition, alkaline phosphatase
levels increased for cells incubated for 48 h in 10 μM of DETA/NO but not SNP [55].
Collectively, this data suggests that the slow release of NO at low concentrations is ideal for
stimulating the proliferation of osteoblasts.
Rapid release of NO only applied intermittently may also be beneficial. Buttery et al. studied
osteocalcin and Cbfa-1/Runx-2 gene expression from osteoblasts supplemented with a rapid
photolabile NO donor, NPR[38]. Osteoblasts derived from both wild-type and eNOS
deficient mice were incubated in 5 μM NPR before UV-light exposure over a period of 1 s
to initiate NO release. This was repeated at each stage of osteoblast growth (i.e.,
proliferation, matrix formation, and matrix mineralization). In eNOS deficient mice, gene
expression was restored to wild-type levels when treated with the NO donor. For wild-type
cells exposed to NO, an increase in Cbfa-1/Runx-2 and osteocalcin expression was observed
at each stage of osteoblast growth [38].
Mechanistically, the enhancement of osteoblast differentiation appears to be dependent on
cGMP [55]. Formed from the activation of soluble guanylate cyclase by NO, cGMP is
responsible for many of NO's biological effects [56, 57]. In the context of bone formation
and repair, cGMP has been shown to enhance alkaline phosphatase and osteocalcin
concentrations [58]. This upregulation is indicative of osteoblast differentiation and
mineralization [59]. The pro-osteogenic cytokine IL-6 is also upregulated by cGMP,
providing an explanation for the proliferative effect of NO on osteoblast cells [60].
However, a cGMP-dependent reduction in alkaline phosphatase is observed at high
concentrations of NO making NO's effects on osteoblasts biphasic [55]. While not entirely
understood, such behavior may be due to the build-up of reactive oxygen species along with
a decline in the cell's mitochondrial membrane potential, ultimately initiating apoptosis [61].
3.2.2. Effects of NO on osteoclasts—Treatment of osteoclasts with exogenous NO
sources causes a variety of effects dependent on NO donor concentration, NO release
duration, and growth conditions. Elevated levels of NO have been shown to cause apoptosis
in osteoclasts. Interestingly, cytokines like interleukin-1 (IL-1) and tumor necrosis factor
(TNF) are known to enhance bone resorption despite the fact that cytokines also elicit the
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upregulation of iNOS [40, 62]. Osteoclasts grown in mouse calvarial organ cultures were
suppressed by interferon gamma, an inducer of iNOS, but only in the presence of IL-1 or
TNF. Similarly, bone resorption resulting from IL-1 was suppressed when cell cultures were
exposed to high concentrations of SNAP (500 μM), but potentiated at low SNAP
concentrations (0.1 – 100 μM) [40], indicating that cytokine-induced bone resorption is
modulated by NO. Consistent with this data, Lee et al. found that TNF upregulates iNOS
and subsequently contributes to TNF-induced osteoclast survival [63]. Mice deficient in
iNOS suffer abnormalities in IL-1 induced bone resorption. Supplementing osteoclasts with
SNAP reversed this inhibition, but only in the presence of IL-1 which the authors attributed
to an NO-dependent enhancement of resorptive pathways signaled by IL-1 [63].
One way that NO may contribute to osteoclastogenesis inhibition is through the production
of osteoprotegerin (OPG). By binding RANKL, OPG halts osteoclast growth and inhibits
bone resorption. When supplemented with 15 μM DETA/NO, bone stromal cells from
ovariectomized rats increased OPG production, resulting in inhibition of osteoclastogenesis
[64]. While supplementation of murine osteoclasts with greater levels of DETA/NO (300
μM) induced apoptosis, increasing IL-1 or RANKL concentrations in the culture medium
decreased apoptosis [64]. Of note, RANKL itself is auto-regulated through NO production.
Osteoclastogenesis stimulated by RANKL is controlled by a negative feedback signal,
whereby RANKL upregulates interferon-β, triggering iNOS-generated NO and inhibiting
bone resorption [65]. These studies suggest that the concentrations of cytokines and other
growth factors must be considered along with NO dose and release rate. This potential
synergy may be of special importance in inflammatory conditions, where cytokine
concentrations are elevated [66].
The effects of exposing osteoclasts to NO also appear to be growth phase dependent. The
activity of osteoclasts treated with either SNP was not affected during the proliferation phase
(1– 3 d), but was inhibited during the differentiation phase (4– 6 d). Once mature, a SNP
concentration of 100 μM SNP was necessary to inhibit the osteoclasts [67]. Osdoby and
colleagues also observed a growth phase-dependence, with NO donors capable of sustained
release (e.g., SNAP) being more effective at inhibiting osteoclastogenesis than donors that
release NO more transiently (e.g., PAPA/NO). This behavior may be attributed to sustained
NO release occurring into the early prefusion development period when the NO donors were
incubated with osteoclast-like cells [39]. This hypothesis is consistent with a report by
Holliday et. al. describing activation of cGMP at low concentrations of exogenously
supplied NO (0.1 μM SNP) that disrupted the formation of osteoclasts, but had little effect
on the proliferation of mature osteoclasts [68]. In contrast, mature osteoclasts respond to
much higher concentrations of NO donor (>100 μM SNP) by both cGMP-independent and
dependents mechanisms [68–71]. While the cGMP-independent mechanisms may rely on
the reaction of NO with superoxide to form peroxynitrite and cause osteoclast detachment
[72], the cGMP-dependent mechanism relies on the activation of protein kinase I by cGMP.
The latter facilitates osteoclast motility and detachment, ultimately reducing bone mineral
matrix degradation [70, 71].
3.3. Systemic NO delivery
The benefits of systemic NO delivery have been highlighted in numerous studies [73–78].
Perhaps the most widely explored systemic uses of NO as a bone therapeutic is for the
treatment of osteoporosis caused by estrogen deficiency via nitroglycerin [46]. In one
example, Wimalawansa et al. compared the effects of estrogen and nitroglycerin therapies
on ovariectomized rats [74]. As expected, diminished bone mineral densities observed in the
ovariectomized rats were reversed with estrogen therapy. As estrogen exerts some of its
action by upregulating eNOS [43], the beneficial effects of estrogen on bone mineral density
reversed when a NOS inhibitor such as L-NAME was administered. Treatment of
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ovariectomized rats with nitroglycerin also reversed bone loss [74, 76], highlighting the
potential of NO as a treatment for osteoporosis while avoiding the adverse consequences
associated with hormone replacement therapy. Indeed, a retrospective analysis of data in a
fracture study showed that women taking nitrates had greater bone mineral densities than
women who did not [73]. After correcting for other health factors, intermittent treatment
with nitrates proved most effective at increasing bone mineral density versus a daily
regiment as frequent administration of nitroglycerin is associated with tolerance [79].
Similarly, a decreased efficacy was observed in rats following ovariectomy as nitroglycerin
treatment frequencies increased from once to three times daily [75].
Despite promise in animal models, studies evaluating the efficacy of nitroglycerin as an
osteoporosis treatment in humans have returned varied results [80]. In a one-year clinical
trial carried out by Wimalawansa et al., nitroglycerin was administered topically to patients
following oophorectomy. The authors observed that nitroglycerin was as effective as
estrogen replacement therapy in preventing bone loss [77]. Unlike estrogen therapy,
however, the nitroglycerin application increased bone formation as evidenced by increased
serum alkaline phosphatase and osteocalcin levels [77]. A second three-year study examined
the effect of nitroglycerin administered daily to post-menopausal women. No difference was
observed between control and nitroglycerin groups, although this finding was attributed to
low adherence (70%) resulting from a side effect of persistent headaches [81]. Most
recently, Jamal et al. conducted a two-year clinical trial that demonstrated topical
nitroglycerin therapy on post-menopausal subjects reduced bone resorption and increased
bone mineral density (Figure 1) [82]. The authors concluded that adherence to a systemic
NO administration regimen may be an effective treatment option for osteoporosis.
3.4. Targeted NO delivery
A promising strategy for delivering NO to bone utilizes bisphosphonates, a class of drugs
that target bone with their propensity to chelate calcium ions [83–89]. Once nitrogen-
containing bisphosphonates accumulate in bone tissue, they are taken up by osteoclasts
where interferences in enzyme syntheses induce apoptosis, decreasing bone resorption and
ultimately contribute to a positive bone balance [3]. Due to their ability to reduce bone
turnover, bisphosphonates represent an effective treatment for disorders that are
characterized by excessive bone resorption such as post-menopausal osteoporosis [83].
Recently, bisphosphonates have been functionalized with organic nitrate NO donors to
target NO to bone more effectively (Figure 4) [83, 90]. The nitrobisphosphonates (i.e.
bisphosphonates functionalized with organic nitrates) inhibited the differentiation of
RANKL-supplemented preosteoclasts (RAW 264.7 cells) into functional osteoclasts.
Addition of 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ), a soluble guanylate
cyclase inhibitor, restored differentiation, indicating that the efficacy against osteoblasts was
a result of NO mediated by cGMP rather than the bisphosphonate itself. Regardless, one
compound proved to be as effective as ibandronate (a clinical bisphosphonate used for the
treatment of osteoporosis) at inhibiting osteoclast formation. The effect of NO-releasing
bisphosphonates on mature osteoclasts was also examined, with the nitrobisphosphonates
reducing the overall number of osteoclasts without affecting their activity [83]. The ability
of the compounds to be taken up selectively into bone tissue (over blood and muscle) was
studied using a radioactive labeling technique [83]. Bisphosphonates containing furoxans, an
additional NO donor classes, were also examined for their ability to inhibit
osteoclastogenesis [90]. Nitric oxide release from these compounds was demonstrated by
their ability to relax rat aorta strips. This vasorelaxation was easily reversed with the
addition of ODQ. Unlike nitrobisphosphonates, the anti-osteoclastogenic effects of the
furoxans were not NO dependent as evidenced by the similar activity of the structurally
similar furazan analogues (which are incapable of NO release). Greater doses of the
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furoxan-functionalized bisphosphonates were required to inhibit pre-osteoclast
differentiation as effectively as the nitrobisphosphonates, presumably due to their alternate
pharmacological mechanism.
3.5. Localized NO delivery
Delivery of NO to bone using macromolecular NO release scaffolds has been shown to
positively affect bone tissue by aiding in fracture and bone healing [47, 91], and lowering
the incidence of infection in external fixation pins [92]. To demonstrate the efficacy of local
NO delivery on fracture healing, Diwan and colleagues surgically implanted an NO-
releasing chitosan derivative (CBC-NONOate) at a femoral fracture site [47]. Chitosan, a
biomaterial that has been used extensively in tissue engineering and drug-delivery [93–95],
is functionalized with amine moieties thereby allowing for straightforward NO storage (via
diazeniumdiolate formation) and NO release. After surgically inducing the fracture, 200 mg
of chitosan or CBC-NONOate was implanted into the adjacent bone tissue. The CBC-
NONOate was capable of delivering 10 μmol of NO to the fracture site over 3 h. After 17 d,
the fracture was assessed with the cross-sectional area of the associated fracture callus
roughly 20% larger than with CBC alone [47].
Nitric oxide release was also shown to benefit the healing of bone defects [91]. In one study,
femoral defects created in adult rats were grafted with a demineralized bone matrix solution
supplemented with S-nitrosobovine serum albumin (SNO-BSA), an analogue of bovine
serum albumin that stores NO through nitrosation of cysteine residues [91]. Approximately
150 nmol of SNO-BSA was delivered to the defect site with equimolar NO release over 10
d. Following a 10 week post-operative period, analysis of the bone tissue showed increased
union across the bone defects in the SNO-BSA group with 62% of the defects exhibiting
union compared to no measureable union in the control group. Enhancements in bone
mineral density and cortex modeling were also observed for the SNO-BSA group [91].
Utilizing the antimicrobial properties of NO to prevent post-operative infections represents
an additional means by which NO may improve clinical treatments of bone. External
fracture fixation pins that become infected often result in failed fracture healing and
osteomyelitis [96]. Microbial biofilms may eventually form on the pin, causing recurring
infections that are difficult to treat and necessitate surgery. Nitric oxide has been reported to
be effective against microbial adhesion [17, 66, 97–101]. To examine whether NO release
would reduce the incidence of infection for external fixation pins, Holt et al. functionalized
titanium external fixation pins with diazeniumdiolate NO donor-functionalized xerogels
(Figure 5) [92]. The NO-releasing pins were implanted into the tail vertebrae of rats and
lowered the incidence of infection compared to controls. Furthermore, the surgical wounds
created by the NO-releasing pin implants showed decreased incidence of edema and
erythema [92]. Combined, these results may be promising for other areas of bone repair, as
infection elicits an inflammatory response that may be harmful to bone tissue [102]. This
study also serves as a reminder that bone tissue does not exist in vacuous isolation; fractures
and surgeries also impact tendons and connective tissues in skin. As NO also regulates
cellular processes in these tissues, we proceed by detailing the role of NO in wound healing
and tendon healing.
4. Nitric oxide in wound healing
Skin, partially composed of connective tissues such as collagen, is the largest organ in the
human body. Wounds occur frequently, with subsequent repair and healing of the skin
taking longer as wound size increases. Upon infliction of a wound, the body responds with a
blood clotting cascade and the infiltration of inflammatory cells [103, 104]. Such action is
initiated by platelet accumulation at the wound site and the release of wound healing
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mediators (e.g., platelet derived growth factor), attracting macrophages and fibroblasts to
assist in the deposition of granulation tissue and collagen [105]. The final deposition of
collagen is essential, as this protein accounts for >70% of the dry weight of skin with the
tensile strength of the closed wound derived from the organized collagen deposition [103,
106, 107]. Several reports describing NO's involvement in reducing platelet adhesion and
aggregation exist, [108–110] suggesting perhaps that NO may negatively impact acute
wound healing, although this may be concentration dependent. Nevertheless, NO may prove
more useful in later stages of wound healing due to the vital role NO plays in influencing
angiogenesis and collagen deposition during the wound-healing cascade [111–113].
While normal fibroblasts do not synthesize NO [114], fibroblasts isolated from wounds have
been shown to release NO. Furthermore, decreased collagen synthesis from the cells has
been reported when NO production in wound fibroblasts was inhibited in vitro by NOS
inhibition [114]. Wound fibroblasts from iNOS knockout mice also showed diminished
collagen deposition with restoration of normal collagen deposition occurring upon exposure
to the NO donor SNAP, indicating a direct connection between NO release and collagen
production [115]. The addition of exogenous NO may also be beneficial in cells with
functioning NOS isoforms as evidenced by enhanced collagen production in normal dermal
fibroblasts exposed to SNAP [116, 117].
A number of studies have examined the effect of reducing NO production in wounds
through chemical inhibition or targeted gene disruption of NOS to determine NO's role in
wound healing [118–123]. Schaffer and coworkers inhibited wound NO synthesis by
intravenous administration of the NOS inhibitors aminoguanidine and S-methyl
isothioronium [118]. Treatment with each of the NOS inhibitors resulted in diminished
hydroxyproline content in the wounded area, indicative of decreased collagen production
[118]. In eNOS knockout mice, wounds required more time to fully close and once closed
the wounds had a lower tensile strength compared to wild-type mice [120]. Likewise,
Yamasaki et al. found that iNOS knockout mice exhibited less wound healing ability [123].
These studies show a clear relationship between healing and normal production of NO by
NOS.
Systemic elevation of NO concentrations using exogenous NO donors has been explored as
a strategy to modulate wound healing. Dietary supplements of arginine, a precursor to NO
generation, has been reported to enhance wound healing in normal but not iNOS knockout
rats, suggesting that supplemental NO enhances healing [119]. The oral administration of
nitronaproxen, an organic nitrate-modified nonsteroidal anti-inflammatory drug (NSAID),
showed large increases (62%) in wound collagen deposition compared to controls [124].
Rather than enhancing systemic levels, Thornton et al. employed simple transfection of the
iNOS gene to wound sites and noted increased collagen production suggesting locally
applied exogenous NO may enhance wound healing [125]. While the exact mechanism by
which NO enhances wound healing remains uncertain, both in vitro and in vivo wound
healing studies indicate that NO promotes collagen synthesis, greatly facilitating the healing
rate and ensuing tissue strength.
4.1 Topical application of nitric oxide in vivo
Given that NO increases collagen deposition at wound sites, it is not surprising that topical
application of NO has also been shown to enhance wound healing. Shekhter et al. simply
exposed the wounds of normal and infected rats to daily doses of NO (500 ppm for 60 s)
[126]. Rats treated with NO experienced an increased rate of wound closure in both aseptic
and infected conditions [126]. After 10 d of NO exposure, the area of the NO-treated aseptic
wounds was almost 50% smaller than those left untreated [126]. Furthermore, infected
wounds treated with NO healed quicker with a ~50% decrease in wound area after 21 d
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[126]. Faster healing has been attributed to the anti-microbial properties of NO and the
killing of bacteria in the wound site [17, 66, 97–101, 127]. While clearly beneficial, such
NO delivery raises toxicity concerns and is impractical from an expense and safety
standpoint (e.g., high pressure gas cylinders, expensive equipment).
As an alternative to gaseous NO, the use of NO donors would simplify the delivery of NO to
wound sites. In an early study performed by Shabani and coworkers, N-diazeniumdiolated
polyethyleneimine cellulose (PEIC-NO) applied to open rat wounds was found to promote
more rapid wound closure compared to control treatments [128]. Likewise, Amadeu et al.
found that application of a hydrogel containing S-nitrosoglutathione (100 μM) to a rat
wound enhanced healing, wound closing time, mast cell infiltration, and resulted in more
organized and mature collagen deposition [129]. In further studies with the S-
nitrosoglutathione containing-hydrogel, Amadeu et al. concluded that delivery of exogenous
NO during both the inflammatory and proliferative stages enhanced healing more than if NO
was applied during only one stage or the other [130].
4.1.1 Burn wounds—In contrast to chronic wounds that may heal, patients with serious
burn wounds often never achieve complete recovery without treatment [131]. Indeed, burn
wounds are of particular importance as they are common, difficult to treat and often lead to
infection; severe burn wounds occur annually at a rate of 5 per 100,000 people [131].
Several groups have investigated NO's role in burn healing and recovery time. Although
indirect, increased nitrate levels in urine were observed following the infliction of a burn
wound in a rat until the wound completely healed [132, 133]. In related research, Paulsen et
al. found that iNOS levels were significantly increased in burned skin [134]. Likewise, the
inhibition of eNOS and iNOS using L-NAME or aminoguanidine was reported to both delay
the healing of thermal wounds and depress vascular hyperpermeability [135, 136].
A major aim in burn wound research is to increase the rate and completeness of healing
[137]. To determine if exogenously administrated NO may fulfill these criteria, Zhu and
coworkers applied NO topically to rat burn wounds using a sodium nitrite gel (14.6 mM) at
reduced pH [138, 139]. Treatment with the NO-releasing gel resulted in quicker wound
closure and increased angiogenesis in addition to an enhanced rate of collagen deposition as
measured by the number of procollagen-positive fibroblasts in the wound over time [138,
139]. Also observed was that topical application of NO to one burn wound did not affect the
healing of other burn wounds on the same animal, proving it necessary to deliver NO locally
and directly to the wound area of interest [139].
4.1.2 Diabetic wounds—Due to NO's role as a healing and antibacterial agent, NO
release may also prove useful as a treatment for diabetic foot ulcers (DFUs). Wound healing
is problematic for diabetics where delayed/diminished healing capability (i.e., collagen
deposition and wound breaking strength) and infection, possibly due to a lack of NO in such
wounds, result in chronic wounds that do not close [140, 141]. Even when glucose levels are
controlled by insulin, diabetic models exhibit diminished nitrate/nitrite levels and collagen
deposition during wound healing compared to non-diabetic animals [140, 142]. To assess
the impact of exogenous NO on wound closure, diabetic rats were fed molsidomine, a
vasodilating drug that is metabolized in the liver to morpholino-sydnonimine (SIN-1) [142–
144]. SIN-1 is a reactive metabolite that releases NO (Figure 7) [144]. The wounds of
molsidomine-fed rats exhibited increased breaking strength and hydroxyproline levels after
10 d of treatment, both indicative of enhanced collagen deposition [142, 143].
While increased NO levels have been shown to enhance wound healing, the localized
delivery of NO at the wound site has only recently been achieved using topical NO donor
application. For example, Weller et al. compared wound healing in normal and diabetic mice
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using a topical treatment of acidified nitrite. Applying the treatment as an aqueous cream
containing 3 and 4.5% (w/v) of sodium nitrite and citric acid, respectively, improved
healing, as quantified by wound area, in both normal and diabetic mice [145]. Although NO
improved wound healing in non-diabetic animals, the rate of healing observed in the diabetic
mice was significantly greater, likely due to the NO deficiencies present in the diabetic
animals [145]. Unfortunately, the topical administration of nitrites may have unfavorable
pro-inflammatory effects, making other NO delivery methods more desirable and beneficial
to wound healing [146].
Concerns about acidified nitrites may be abrogated using NO donors that spontaneously
release NO (e.g. N-diazeniumdiolates). Dashti and coworkers measured collagen production
of NO-treated and untreated wounds in a diabetic rat model by implanting polyvinyl alcohol
sponges and administering 100 μM DETA/NO in phosphate buffered saline at 3 d intervals
[147]. After 6 days, the sponges were explanted and protein analysis of the wound fluid
revealed enhanced collagen production for the NO-treated wounds [147]. Li and colleagues
covered wounds with a poly(vinyl methyl ether-co-maleic anhydride) (PVMMA) and
poly(vinyl pyrrolidone) (PVP) hybrid polymer modified with S-nitrosothiolglutathione or
phytochelatin residues to diabetic rat wounds [148]. These nitrosated polymers released
approximately 50 nmol NO per mg of nanoparticles over 12 d at 37 °C in ambient light
[148]. As such, μmol levels of NO were released into the wound bed subsequently
accelerating wound closure at 4, 7 and 10 d post-wound infliction as determined by a
decrease in wound area [148]. Despite these initial feasibility studies, much remains
unknown regarding the ideal NO release kinetics and amounts required to facilitate wound
healing.
Of note, the increased rate of infection in diabetic wounds make individuals with diabetes a
high-risk group for orthopedic infections [149]. By utilizing an NO-releasing orthopedic
implant similar to that discussed in section 3.5, complications associated with orthopedic
device infections in both diabetic and non-diabetic rats should be assessed. Overcoming
bacterial colonization in bone and the surrounding tissue through the release of NO may
reduce the rate of implant-associated infections, ultimately reducing failure rates and
increasing the quality of orthopedic care for diabetic patients.
5. Nitric oxide in tendon healing
Tendons are an integral part of the mammalian musculoskeletal system and act to transfer
force created by muscles to movement of bones [150]. Collagen is a major component of
these connective tissues, accounting for >70% of the tendon dry weight [150]. Injuries to
tendons due to overuse, termed tendinopathy, currently have limited treatment options [151].
Nitric oxide's role in tendon repair is based on the ability to promote collagen deposition and
strengthen this tissue. Several studies have shown that reduced NO production inhibits
tendon healing and collagen synthesis [152, 153]. Nitric oxide release from fibroblasts
promotes collagen synthesis, further highlighting the potential of NO-releasing therapies in
tendon repair [114, 117, 152]. For example, Murrell and coworkers reported that cultured
tendon cells treated with SNAP altered their collagen synthesis in a dose dependent manner
[154, 155]. Low concentrations of SNAP (<100 μM) had no effect on collagen synthesis. In
contrast, much larger SNAP concentrations (800 μM) impeded collagen synthesis [155].
Intermediate concentrations of SNAP (100 and 400 μM) significantly promoted collagen
synthesis, emphasizing the importance of NO donor dose [155]. The mRNA expression
from cultured tenocytes for a number of proteins indicated that the most optimal healing
may be achieved by varying the dose of NO from a high initial concentration to a low
concentration over time [154]. Collectively, these studies highlight the potential of NO to
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treat tendon injury and show the need to control localized NO concentrations to promote and
not inhibit collagen deposition [154, 156].
5.1 Delivery of nitric oxide to tendons in vivo
A number of pre-clinical studies support the utility of exogenous NO to promote tendon
healing. Lin et al. reported a time-dependent upregulation of the three NOS isoforms (eNOS,
iNOS and nNOS) after wounding of the Achilles tendons in rats [157, 158]. Inhibition of the
NOS proteins during the healing of ruptured Achilles tendons in rats resulted in a reduced
cross-sectional area of the healing tendon [156]. Yuan et al. found that daily and localized
injection of NO-generating nitroflurbiprofen improved collagen organization and tendon
stress in rats with injured Achilles tendons 10 d post-injury relative to controls [159].
Similarly, the effect of injecting nitroparacetamol (48 mg kg−1 per day) at wounded Achilles
tendons in rats had no significant effect on the failure load of the tendons, but the treatment
increased both collagen organization and content [160].
Investigation of tendon healing in human patients has focused on topical administration of
NO donors, a treatment that is much simpler and less likely to disrupt surrounding tissue.
FDA-approved nitroglycerin patches have been tested on human patients and proven useful
due to their analgesic effects for painful tendon injuries [161]. In addition to pain reduction,
the nitroglycerin patches improved the likelihood of complete healing after six months of
treatment [162–164]. A three-year follow-up study of nitroglycerin patch treatment of
chronic noninsertional Achilles tendinopathy reported that patients who used the NO-
producing patches for six months were more asymptomatic than those receiving placebos,
providing evidence of the benefits of NO on long-term healing of tendons [165]. Though
these results appear promising, other studies have found no differences between NO
treatment and control groups in similar short-term studies and long-term follow-ups [166–
168]. For example, an eight-week study by Paolini et al. examined the dose-dependence of
topical nitroglycerin for the treatment of chronic lateral epicondylosis, but the only observed
effect was a reduction in elbow pain for one dosage of nitroglycerin [168]. Of note,
treatments that were previously successful were based on the use of nitroglycerin patches
and a longer treatment period in conjunction with physical therapy [162, 168]. While the use
of nitroglycerin patches is convenient due to their FDA status, it would be useful to test
other NO donors as nitroglycerin has adverse side effects (e.g., headaches) that cause non-
compliance [162–164]. Furthermore, prolonged use of organic nitrates may lead to
tolerance, diminishing treatment benefits. Further studies must determine the role of NO
administration and amount of NO release on tendon healing. Clearly, the importance of
physical therapy on tendon healing with and in the absence of NO should be ascertained.
Additionally, the amount of actual NO delivery must be more carefully reported since NO-
donor concentrations alone rarely correlate with NO release kinetics and lifetimes across
NO-donor chemical structures.
6. Conclusion and outlook
To limit complex signaling cascades that may convolute data and provide undesirable side
effects during treatment, localizing delivery of NO has proven essential for a number of
biological applications, especially considering its short half-life and limited sphere of
influence. Thus far, the primary strategies utilized for treatment of bones with NO involve
systemic transdermal uptake of organic nitrates or implantation of NO donors at the site of
injury. A number of examples have also appeared describing localized NO release from the
surfaces of bone plates and screws in vivo (e.g., NO-releasing xerogels), though the use of
an implantable material limits treatment to applications requiring surgery. Surgical
procedures may be avoided with the use of targeted NO release achieved with NO-releasing
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bisphosphonates. Additional studies utilizing such NO donors in vivo will contribute needed
evidence for their efficacy in bone healing.
Wound healing models have implemented a wide range of NO donor types and
concentrations. The advantages of NO release in wound healing have been shown in several
instances, but little work has focused on the topical treatment of burns or diabetic wounds.
These two types of wounds represent slow-healing chronic challenges that may benefit
greatly from NO's accelerated healing attributes. To date, most research in these areas has
utilized NO-releasing nanoparticles or potentially pro-inflammatory sources of NO (e.g.,
nitrite gels) that ultimately may negatively impact the overall tissue response. Future studies
should carefully consider the NO donor used, specifically elucidating the role that NO-
release kinetics may have on wound healing.
Examples of applying NO donors to tendons have exclusively focused on the use of organic
nitrates. These molecules provide some advantages, but the potential of forming tolerance
and undesirable side effects may preclude their clinical utility. The need to assess the
efficacy of other NO donor molecules that may circumvent the problems of organic nitrates
while maintaining suitable biocompatibility is great. Such NO donors would likely be
administered by direct injection or via a transdermal patch to maximize delivery of NO to
the injury site. Furthermore, a connection between NO delivery and physical therapy should
be explored as it may prove to be an important factor in the efficacy of NO treatment for
tendon injuries.
In closing, a number of questions remain regarding the optimal dose of NO necessary to
modulate the repair of bone, skin, and tendon tissues. Most in vivo studies to date have
employed organic nitrates, an inherently challenging NO donor to work with due to a non-
spontaneous NO release mechanism, as well as undesirable side effects and evolving
tolerance. Studies utilizing NO donors that release NO by more spontaneous mechanisms
(e.g., N-diazeniumdiolates and S-nitrosothiols) should be more carefully considered to better
evaluate controlled, localized delivery of NO as a therapy. Appropriate testing of such
donors should be undertaken both in vitro and in vivo to ascertain the role of NO-release
kinetics and NO flux on bone, skin, and tendon healing. The most promising materials
should then be evaluated clinically.
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Abbreviations
CBC-NONOate N-diazeniumdiolate-functionalized chitosan
cGMP cyclic guanosine monophosphate
DETA/NO 1-N-(aminoethyl)-N-(2-ammonioethyl)amino] diazen-1-ium-1,2-
diolate
DFU diabetic foot ulcer
eNOS endothelial nitric oxide synthase
GSNO S-nitrosoglutathione
iNOS inducible nitric oxide synthase
L-NAME L-NG-nitroarginine methyl ester
Nichols et al. Page 13














mtALDH mitochondrial aldehyde dehydrogenase
NO nitric oxide
nNOS neuronal nitric oxide synthase
NOS nitric oxide synthase
NPR potassium nitrosylpentachlororuthenate





PEIC-NO N-diazeniumdiolated polyethyleneimine cellulose
PVMMA poly(vinyl methyl ether-comaleic anhydride)
PVP poly(vinyl pyrrolidone)
RANKL receptor activator of nuclear factor kappa-B ligand
SIN-1 morpholino-sydnonimine
SNAP S-nitroso-N-acetyl-penicillamine
SNO-BSA S-nitrosobovine serum albumin
SNP sodium nitroprusside
IL-1 interleukin-1
TNF tumor necrosis factor
References
[1]. Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies.
Chem. Soc. Rev. 2006; 35:780–789. [PubMed: 16936926]
[2]. Simchi A, Tamjid E, Pishbin F, Boccaccini AR. Recent progress in inorganic and composite
coatings with bactericidal capability for orthopaedic applications. Nanomed. Nanotechnol. Biol.
Med. 2011; 7:22–39.
[3]. Rodan GA, Martin TJ. Therapeutic Approaches to Bone Diseases. Science. 2000; 289:1508–1514.
[PubMed: 10968781]
[4]. Bilezikian, JP.; Raisz, LG.; Rodan, GA. Principles of bone biology. Academic Press; San Diego:
1996.
[5]. Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing.
Injury. 2005; 36:1392–1404. [PubMed: 16102764]
[6]. Laurencin CT, Ambrosio AMA, Borden MD, Cooper JA. Tissue Engineering: Orthopedic
Applications. Annu. Rev. Biomed. Eng. 1999; 1:19–46. [PubMed: 11701481]
[7]. Ignarro, LJ. Nitric oxide: biology and pathobiology. Academic; San Diego, Calif.: London: 2000.
[8]. Williams DLH. A chemist's view of the nitric oxide story. Org. Biomol. Chem. 2003; 1:441–449.
[PubMed: 12926240]
[9]. Griffith OW, Stuehr DJ. Nitric Oxide Synthases: Properties and Catalytic Mechanism. Annu. Rev.
Physiol. 1995; 57:707–734. [PubMed: 7539994]
Nichols et al. Page 14













[10]. Malinski T, Taha Z, Grunfeld S, Patton S, Kapturczak M, Tomboulian P. Diffusion of Nitric
Oxide in the Aorta Wall Monitored in Situ by Porphyrinic Microsensors. Biochem. Biophys. Res.
Commun. 1993; 193:1076–1082. [PubMed: 8323533]
[11]. Nablo BJ, Prichard HL, Butler RD, Klitzman B, Schoenfisch MH. Inhibition of implant-
associated infections via nitric oxide release. Biomaterials. 2005; 26:6984–6990. [PubMed:
15978663]
[12]. Hrabie JA, Keefer LK. Chemistry of the nitric oxide-releasing diazeniumdiolate
(“nitrosohydroxylamine”) functional group and its oxygen-substituted derivatives. Chem. Rev.
2002; 102:1135–1154. [PubMed: 11942789]
13. Davies KM, Wink DA, Saavedra JE, Keefer LK. Chemistry of the diazeniumdiolates. 2. Kinetics
and mechanism of dissociation to nitric oxide in aqueous solution. J. Am. Chem. Soc. 2001;
123:5473–5481. [PubMed: 11389629]
[14]. Williams DLH. The chemistry of S-nitrosothiols. Accounts Chem. Res. 1999; 32:869–876.
[15]. Seabra AB, Duran N. Nitric oxide-releasing vehicles for biomedical applications. J. Mater.
Chem. 2010; 20:1624–1637.
[16]. Keefer LK, Nims RW, Davies KM, Wink DA. “NONOates” (1-substituted diazen-1-ium-1,2-
diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol. 1996;
268:281–293. [PubMed: 8782594]
[17]. Riccio DA, Dobmeier KP, Hetrick EM, Privett BJ, Paul HS, Schoenfisch MH. Nitric oxide-
releasing S-nitrosothiol-modified xerogels. Biomaterials. 2009; 30:4494–4502. [PubMed:
19501904]
[18]. Shin JH, Metzger SK, Schoenfisch MH. Synthesis of nitric oxide-releasing silica nanoparticles. J.
Am. Chem. Soc. 2007; 129:4612–4619. [PubMed: 17375919]
[19]. Shin JH, Schoenfisch MH. Inorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide
Delivery Scaffold. Chem. Mater. 2008; 20:239–249.
[20]. Riccio DA, Nugent JL, Schoenfisch MH. Stober Synthesis of Nitric Oxide-Releasing
SNitrosothiol-Modified Silica Particles. Chem. Mater. 2011; 23:1727–1735. [PubMed:
21499510]
[21]. Stasko NA, Schoenfisch MH. Dendrimers as a scaffold for nitric oxide release. J. Am. Chem.
Soc. 2006; 128:8265–8271. [PubMed: 16787091]
[22]. Stasko NA, Fischer TH, Schoenfisch MH. S-nitrosothiol-modified dendrimers as nitric oxide
delivery vehicles. Biomacromolecules. 2008; 9:834–841. [PubMed: 18247567]
[23]. Mowery KA, Schoenfisch MH, Saavedra JE, Keefer LK, Meyerhoff ME. Preparation and
characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide
release. Biomaterials. 2000; 21:9–21. [PubMed: 10619674]
[24]. Parzuchowski PG, Frost MC, Meyerhoff ME. Synthesis and Characterization of
Polymethacrylate-Based Nitric Oxide Donors. J. Am. Chem. Soc. 2002; 124:12182–12191.
[PubMed: 12371858]
[25]. Coneski PN, Rao KS, Schoenfisch MH. Degradable Nitric Oxide-Releasing Biomaterials via
Post-Polymerization Functionalization of Cross-Linked Polyesters. Biomacromolecules. 2010;
11:3208–3215.
[26]. Coneski PN, Nash JA, Schoenfisch MH. Nitric Oxide-Releasing Electrospun Polymer
Microfibers. ACS Appl. Mater. Interfaces. 2011; 3:426–432. [PubMed: 21250642]
[27]. Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, Janczuk AJ. Nitric Oxide Donors: Chemical
Activities and Biological Applications. Chem. Rev. 2002; 102:1091–1134. [PubMed: 11942788]
[28]. Murad F. The excitement and rewards of research with our discovery of some of the biological
effects of nitric oxide. Circ. Res. 2003; 92:339–341. [PubMed: 12623869]
[29]. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin
bioactivation. PNAS. 2002; 99:8306–8311. [PubMed: 12048254]
[30]. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T, Kitagawa K, Nakayama KI,
Hess DT, Stamler JS. An essential role for mitochondrial aldehyde dehydrogenase in
nitroglycerin bioactivation. PNAS. 2005; 102:12159–12164. [PubMed: 16103363]
[31]. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mülsch A, Schulz E,
Keaney J. John F. Stamler JS, Münzel T. Central role of mitochondrial aldehyde dehydrogenase
Nichols et al. Page 15













and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J. Clin. Invest. 2004;
113:482–489. [PubMed: 14755345]
[32]. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M, Kleschyov
AL, Stalleicken D, Ullrich V, M ü lsch A, M ü nzel T. Oxidative Stress and Mitochondrial
Aldehyde Dehydrogenase Activity: A Comparison of Pentaerythritol Tetranitrate with Other
Organic Nitrates. Mole. Pharmacol. 2004; 66:1372–1382.
[33]. McCleverty JA. Chemistry of Nitric Oxide Relevant to Biology. Chem. Rev. 2004; 104:403–418.
[PubMed: 14871130]
[34]. Yip K-P. Flash photolysis of caged nitric oxide inhibits proximal tubular fluid reabsorption in
free-flow nephron. Am. J. Physiol.-Reg. I. 2005; 289:R620–R626.
[35]. Bettache N, Carter T, Corrie JET, Ogden D, Trentham DR. Photolabile donors of nitric oxide:
Ruthenium nitrosyl chlorides as caged nitric oxide. Methods Enzymol. 1996; 268:266–281.
[PubMed: 8782593]
[36]. Teitelbaum SL. Bone Resorption by Osteoclasts. Science. 2000; 289:1504–1508. [PubMed:
10968780]
[37]. Aguirre J, Buttery L, O'Shaughnessy M, Afzal F, Fernandez de Marticorena I.g. Hukkanen M,
Huang P, MacIntyre I, Polak J. Endothelial Nitric Oxide Synthase Gene-Deficient Mice
Demonstrate Marked Retardation in Postnatal Bone Formation, Reduced Bone Volume, and
Defects in Osteoblast Maturation and Activity. Am. J. Pathol. 2001; 158:247–257. [PubMed:
11141498]
[38]. Afzal F, Polak J, Buttery L. Endothelial nitric oxide synthase in the control of osteoblastic
mineralizing activity and bone integrity. J. Pathol. 2004; 202:503–510. [PubMed: 15095278]
[39]. Collin-Osdoby P, Rothe L, Bekker S, Anderson F, Osdoby P. Decreased Nitric Oxide Levels
Stimulate Osteoclastogenesis and Bone Resorption Both in Vitro and in Vivo on the Chick
Chorioallantoic Membrane in Association with Neoangiogenesis. J. Bone Miner. Res. 2000;
15:474–488. [PubMed: 10750562]
[40]. Ralston SH, Ho L-P, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: A
cytokine-induced regulator of bone resorption. J. Bone Miner. Res. 1995; 10:1040–1049.
[PubMed: 7484279]
[41]. Nilforoushan D, Gramoun A, Glogauer M, Manolson MF. Nitric oxide enhances
osteoclastogenesis possibly by mediating cell fusion. Nitric Oxide-Biol. Chem. 2009; 21:27–36.
[42]. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of
murine osteoclasts mediated by TGF-[beta]. Nat. Med. 1996; 2:1132–1136. [PubMed: 8837613]
[43]. Armour KE, Ralston SH. Estrogen Upregulates Endothelial Constitutive Nitric Oxide Synthase
Expression in Human Osteoblast-Like Cells. Endocrinology. 1998; 139:799–802. [PubMed:
9449657]
[44]. O'Shaughnessy MC, Polak JM, Afzal F, Hukkanen MVJ, Huang P, MacIntyre I, Buttery LDK.
Nitric Oxide Mediates 17[beta]-Estradiol-Stimulated Human and Rodent Osteoblast Proliferation
and Differentiation. Biochem. Biophys. Res. Commun. 2000; 277:604–610. [PubMed:
11062001]
[45]. Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, Ralston SH.
Defective Bone Formation and Anabolic Response to Exogenous Estrogen in Mice with Targeted
Disruption of Endothelial Nitric Oxide Synthase. J. Endocrinol. 2001; 142:760–766.
[46]. Wimalawansa SJ. Nitric oxide: novel therapy for osteoporosis. Expert Opin. Pharmacother. 2008;
9:3025–3044. [PubMed: 19006476]
[47]. Diwan AD, Wang MX, Jang D, Zhu W, Murrell GAC. Nitric Oxide Modulates Fracture Healing.
J. Bone Miner. Res. 2000; 15:342–351. [PubMed: 10703937]
[48]. Baldik Y, Diwan AD, Appleyard RC, Ming Fang Z, Wang Y, Murrell GAC. Deletion of iNOS
gene impairs mouse fracture healing. Bone. 2005; 37:32–36. [PubMed: 15894526]
[49]. Rubin J, Murphy T, Nanes MS, Fan X. Mechanical strain inhibits expression of osteoclast
differentiation factor by murine stromal cells. Am. J. Physiol-Cell Ph. 2000; 278:C1126–C1132.
[50]. Rubin J, Fan X, Biskobing DM, Taylor WR, Rubin CT. Osteoclastogenesis is repressed by
mechanical strain in an in vitro model. J. Orthopaed. Res. 1999; 17:639–645.
Nichols et al. Page 16













[51]. Rangaswami H, Marathe N, Zhuang S, Chen Y, Yeh J-C, Frangos JA, Boss GR, Pilz RB. Type II
cGMP-dependent Protein Kinase Mediates Osteoblast Mechanotransduction. J. Biol. Chem.
2009; 284:14796–14808. [PubMed: 19282289]
[52]. Rubin J, Murphy TC, Zhu L, Roy E, Nanes MS, Fan X. Mechanical Strain Differentially
Regulates Endothelial Nitric-oxide Synthase and Receptor Activator of Nuclear KB Ligand
Expression via ERK1/2 MAPK. J. Biol. Chem. 2003; 278:34018–34025. [PubMed: 12824189]
[53]. Rahnert J, Fan X, Case N, Murphy TC, Grassi F, Sen B, Rubin J. The role of nitric oxide in the
mechanical repression of RANKL in bone stromal cells. Bone. 2008; 43:48–54. [PubMed:
18440890]
[54]. Otsuka E, Hirano K, Matsushita S, Inoue A, Shigehisa H, Yamaguchi A, Hagiwara H. Effects of
nitric oxide from exogenous nitric oxide donors on osteoblastic metabolism. Eur. J. Pharmacol.
1998; 349:345–350. [PubMed: 9671116]
[55]. Mancini L, Moradi-Bidhendi N, Becherini L, Martineti V, MacIntyre I. The Biphasic Effects of
Nitric Oxide in Primary Rat Osteoblasts Are cGMP Dependent. Biochem. Biophys. Res.
Commun. 2000; 274:477–481. [PubMed: 10913363]
[56]. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion
to vascular endothelium. Biochem. Biophys. Res. Commun. 1987; 148:1482–1489. [PubMed:
2825688]
[57]. Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble
guanylatecyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein -
Stimulation by acetylcholine, bradykinn and arachidonic-acid. J. Pharmacol. Exp. Ther. 1986;
237:893–900. [PubMed: 2872327]
[58]. Hagiwara H, Inoue A, Yamaguchi A, Yokose S, Furuya M, Tanaka S, Hirose S. cGMP produced
in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am.
J. Physiol.-Cell Physiol. 1996; 270:C1311–C1318.
[59]. Otsuka E, Hirano K, Matsushita S, Inoue A, Hirose S, Yamaguchi A, Hagiwara H. Effects of
nitric oxide from exogenous nitric oxide donors on osteoblastic metabolism. Eur. J. Pharmacol.
1998; 349:345–350. [PubMed: 9671116]
[60]. Broderick KE, Zhang T, Rangaswami H, Zeng Y, Zhao X, Boss GR, Pilz RB. Guanosine 3 ',5'-
cyclic monophosphate (cGMP)/cGMP-dependent protein kinase induce interleukin-6
transcription in osteoblasts. Mol. Endocrinol. 2007; 21:1148–1162. [PubMed: 17341596]
[61]. Chen RM, Chen TL, Chiu WT, Chang CC. Molecular mechanism of nitric oxide-induced
osteoblast apoptosis. J. Orthop. Res. 2005; 23:462–468. [PubMed: 15734263]
[62]. Van 't Hof RJ, Ralston SH. Cytokine-induced nitric oxide inhibits bone resorption by inducing
apoptosis of osteoclast progenitors and suppressing osteoclast activity. J. Bone Miner. Res. 1997;
12:1797–1804. [PubMed: 9383684]
[63]. Lee SK, Huang H, Lee SW, Kim KH, Kim KK, Kim H-M, Lee ZH, Kim H-H. Involvement of
iNOS-dependent NO production in the stimulation of osteoclast survival by TNF-[alpha]. Exp.
Cell. Res. 2004; 298:359–368. [PubMed: 15265685]
[64]. Kanaoka K, Kobayashi Y, Hashimoto F, Nakashima T, Shibata M, Kobayashi K, Kato Y, Sakai
H. A Common Downstream Signaling Activity of Osteoclast Survival Factors That Prevent
Nitric Oxide-Promoted Osteoclast Apoptosis. J. Endocrinol. 2000; 141:2995–3005.
[65]. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates inducible nitric-oxide synthase
expression and nitric oxide production in developing osteoclasts - An autocrine negative
feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappa B that restrains
osteoclastogenesis and bone resorption. J. Biol. Chem. 2006; 281:15809–15820. [PubMed:
16613848]
[66]. Hetrick EM, Schoenfisch MH. Antibacterial nitric oxide-releasing xerogels: Cell viability and
parallel plate flow cell adhesion studies. Biomaterials. 2007; 28:1948–1956. [PubMed:
17240444]
[67]. Holliday LS, Dean AD, Lin RH, Greenwald JE, Gluck SL. Low NO concentrations inhibit
osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism. Am. J. Physol.-
Renal. 1997; 272:F283–F291.
Nichols et al. Page 17













[68]. Holliday LS, Dean AD, Lin RH, Greenwald JE, Gluck SL. Low NO concentrations inhibit
osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism. Am. J.
Physiol.-Renal Physiol. 1997; 272:F283–F291.
[69]. MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, Hecker M, Vane JR.
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. PNAS. 1991;
88:2936–2940. [PubMed: 1849281]
[70]. Yaroslavskiy BB, Zhang YJ, Kalla SE, Palacios VG, Sharrow AC, Li YN, Zaidi M, Wu CY,
Blair HC. NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and
VASP. J. Cell Sci. 2005; 118:5479–5487. [PubMed: 16291726]
[71]. Yaroslavskiy BB, Li YN, Ferguson DJP, Kalla SE, Oakley JI, Blair HC. Autocrine and paracrine
nitric oxide regulate attachment of human osteoclasts. J. Cell. Biochem. 2004; 91:962–972.
[PubMed: 15034931]
[72]. Mancini L, Moradi-Bidhendi N, Brandi ML, MacIntyre I. Nitric oxide superoxide and
peroxynitrite modulate osteoclast activity. Biochem. Biophys. Res. Commun. 1998; 243:785–
790. [PubMed: 9501002]
[73]. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent Use of Nitrates Increases Bone
Mineral Density: The Study of Osteoporotic Fractures. J. Bone Miner. Res. 1998; 13:1755–1759.
[PubMed: 9797485]
[74]. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates
ovariectomy-induced bone loss. Bone. 1996; 18:301–304. [PubMed: 8726385]
[75]. Wimalawansa S, Chapa T, Fang L, Yallampalli C, Simmons D, Wimalawansa S. Frequency-
Dependent Effect of Nitric Oxide Donor Nitroglycerin on Bone. J. Bone Miner. Res. 2000;
15:1119–1125. [PubMed: 10841180]
[76]. Hukkanen M, Platts LAM, Lawes T, Girgis SI, Konttinen YT, Goodship AE, MacIntyre I, Polak
JM. Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen
deficiency-induced osteopenia. Bone. 2003; 32:142–149. [PubMed: 12633786]
[77]. Wimalawansa SJ. Nitroglycerin Therapy Is as Efficacious as Standard Estrogen Replacement
Therapy (Premarin) in Prevention of Oophorectomy-Induced Bone Loss: A Human Pilot Clinical
Study. J. Bone Miner. Res. 2000; 15:2240–2244. [PubMed: 11092405]
[78]. Kdolsky R, Mohr W, Savidis-Dacho H, Beer R, Puig S, Reihsner R, Tangl S, Donath K. The
influence of oral L-arginine on fracture healing: an animal study. Wien. Klin. Wochenschr. 2005;
117:693–701. [PubMed: 16416369]
[79]. Agvald P, Adding LC, Gustafsson LE, Persson MG. Nitric oxide generation, tachyphylaxis and
cross-tachyphylaxis from nitrovasodilators in vivo. Eur. J. Pharmacol. 1999; 385:137–145.
[PubMed: 10607869]
[80]. Khosla S. Is Nitroglycerin a Novel and Inexpensive Treatment for Osteoporosis? J. Am. Med.
Ass. 2011; 305:826–827.
[81]. Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal Nitroglycerin Therapy May
Not Prevent Early Postmenopausal Bone Loss. J. Clin. Endocr. Metab. 2009; 94:3356–3364.
[PubMed: 19549739]
[82]. Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of Nitroglycerin Ointment on Bone
Density and Strength in Postmenopausal Women. J. Am. Med. Ass. 2011; 305:800–807.
[83]. Lazzarato L, Rolando B, Lolli ML, Tron GC, Fruttero R, Gasco A, Deleide G, Guenther HL.
Synthesis of NO-Donor Bisphosphonates and Their in-Vitro Action on Bone Resorption. J. Med.
Chem. 2005; 48:1322–1329. [PubMed: 15743175]
[84]. Zhang SF, Gangal G, Uludag H. 'Magic bullets' for bone diseases: progress in rational design of
bone-seeking medicinal agents. Chem. Soc. Rev. 2007; 36:507–531. [PubMed: 17325789]
[85]. Fleisch HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann. Med. 1997;
29:55–62. [PubMed: 9073324]
[86]. Papapoulos SE, Landman JO, Bijvoet OLM, Lowik C, Valkema R, Pauwels EKJ, Vermeij P. The
use of bisphosphonates in the treatment of osteoporosis. Bone. 1992; 13:S41–S49. [PubMed:
1581119]
[87]. Bone HG, Hosking D, Devogelaer J, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA,
Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase IIO. Ten years' experience
Nichols et al. Page 18













with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004; 350:1189–
1199. [PubMed: 15028823]
[88]. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguezportales J, Downs
RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah
RV, Hirsch LJ, Karpf DB. Effect of oral alendronate on bone-mineral density and the incidence
of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995; 333:1437–1443. [PubMed:
7477143]
[89]. Oura S, Hirai I, Yoshimasu T, Kokawa Y, Sasaki R, Okamura Y. Clinical efficacy of
bisphosphonate therapy for bone metastasis from breast cancer. Beast Cancer. 2003; 10:28–32.
[90]. Lolli ML, Rolando B, Tosco P, Chaurasia S, Stilo AD, Lazzarato L, Gorassini E, Ferracini R,
Oliaro-Bosso S, Fruttero R, Gasco A. Synthesis and preliminary pharmacological
characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorg. Med.
Chem. 2010; 18:2428–2438. [PubMed: 20299227]
[91]. Baldik Y, Talu U, Altinel L, Bilge H, Demiryont M, Aykac-Toker G. Bone Healing Regulated by
Nitric Oxide: An Experimental Study in Rats. Clin. Orthop. Rel. Res. 2002; 404:343–352.
[92]. Holt J, Hertzberg B, Weinhold P, Storm W, Schoenfisch M, Dahners L. Decreasing Bacterial
Colonization of External Fixation Pins Through Nitric Oxide Release Coatings. J. Orthop.
Trauma. 2011; 25:432–437. 410. 1097/BOT.1090b1013e3181f1099ac1098a. [PubMed:
21637124]
[93]. Madihally SV, Matthew HWT. Porous chitosan scaffolds for tissue engineering. Biomaterials.
1999; 20:1133–1142. [PubMed: 10382829]
[94]. Sudarshan NR, Hoover DG, Knorr D. Antibacterial action of chitosan. Food Biotechnol. 1992;
6:257–272.
[95]. Ravi Kumar M. A review of chitin and chitosan applications. React. Funct. Polym. 2000; 46:1–
27.
[96]. Coester LM, Nepola JV, Allen J, Marsh JL. The Effects of Silver Coated External Fixation Pins.
Iowa Orthop J. 2006; 26:48–53. [PubMed: 16789449]
[97]. Charville GW, Hetrick EM, Geer CB, Schoenfisch MH. Reduced bacterial adhesion to
fibrinogen-coated substrates via nitric oxide release. Biomaterials. 2008; 29:4039–4044.
[PubMed: 18657857]
[98]. Dobmeier KP, Schoenfisch MH. Antibacterial properties of nitric oxide-releasing sol-gel
microarrays. Biomacromolecules. 2004; 5:2493–2495. [PubMed: 15530068]
[99]. Nablo BJ, Chen TY, Schoenfisch MH. Sol-gel derived nitric-oxide releasing materials that
reduce bacterial adhesion. J. Am. Chem. Soc. 2001; 123:9712–9713. [PubMed: 11572708]
[100]. Nablo BJ, Schoenfisch MH. Antibacterial properties of nitric oxide-releasing sol-gels. J.
Biomed. Mater. Res. Part A. 2003; 67A:1276–1283.
[101]. Privett BJ, Nutz ST, Schoenfisch MH. Efficacy of surface-generated nitric oxide against
Candida albicans adhesion and biofilm formation. Biofouling. 2010; 26:973–983. [PubMed:
21082455]
[102]. Thomas MV, Puleo DA. Infection, Inflammation, and Bone Regeneration. J. Dent. Res. 2011;
90:1052–1061. [PubMed: 21248364]
[103]. Alvarez, OM.; Goslen, JB.; Eaglstein, WH.; Welgus, HG.; Stricklin, GP. Biology of the dermis:
wound healing. In: Fitzpatrick, TB.; Eisen, AZ.; Wolff, K.; Freedber, IM.; Austen, KF., editors.
Dermatology in general medicine. McGraw Hill Book Co.; New York: 1987. p. 1-1598.
[104]. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol.
Rev. 2003; 83:835–870. [PubMed: 12843410]
[105]. Singer AJ, Clark RAF. Mechanisms of disease - Cutaneous wound healing. N. Engl. J. Med.
1999; 341:738–746. [PubMed: 10471461]
[106]. Uitto, J.; Eisen, AZ. Biology of the dermis: collagen. In: Fitzpatrick, TB.; Eisen, AZ.; Wolff, K.;
Freedber, IM.; Austen, KF., editors. Dermatology in general medicine. McGraw Hill Book Co.;
New York: 1987. p. 1-1598.
[107]. Bauer EA, Uitto J. Collagen in cutaneous diseases. Int. J. Dermatol. 1979; 18:251–270.
[PubMed: 222699]
Nichols et al. Page 19













[108]. Tymvios C, Moore C, Jones S, Solomon A, Sanz-Rosa D, Emerson M. Platelet aggregation
responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric
oxide synthase. Br. J. Pharmacol. 2009; 158:1735–1742. [PubMed: 19912226]
[109]. Moore C, Tymvios C, Emerson M. Functional regulation of vascular and platelet activity during
thrombosis by nitric oxide and endothelial nitric oxide synthase. Thromb. Haemost. 2010;
104:342–349. [PubMed: 20508906]
[110]. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet-
adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 1987; 148:1482–1489.
[PubMed: 2825688]
[111]. Rizk M, Witte MB, Barbul A. Nitric oxide and wound healing. World J.Surg. 2004; 28:301–
306. [PubMed: 14961192]
[112]. Witte MB, Barbul A. Role of nitric oxide in wound repair. Am. J. Surg. 2002; 183:406–412.
[PubMed: 11975928]
[113]. Cooke JP. NO and angiogenesis. Atheroscler. Suppl. 2003; 4:53–60. [PubMed: 14664903]
[114]. Schaffer MR, Efron PA, Thornton FJ, Klingel K, Gross SS, Barbul A. Nitric oxide, an autocrine
regulator of wound fibroblast synthetic function. J. Immunol. 1997; 158:2375–2381. [PubMed:
9036987]
[115]. Shi HP, Efron DT, Most D, Barbul A. The role of iNOS in wound healing. Surgery. 2001;
130:225–229. [PubMed: 11490353]
[116]. Obayashi K, Akamatsu H, Okano Y, Matsunaga K, Masaki H. Exogenous nitric oxide enhances
the synthesis of type I collagen and heat shock protein 47 by normal human dermal fibroblasts. J.
Dermatol. Sci. 2006; 41:121–126. [PubMed: 16171977]
[117]. Witte MB, Thornton FJ, Efron DT, Barbul A. Enhancement of fibroblast collagen synthesis by
nitric oxide. Nitric Oxide-Biol. Chem. 2000; 4:572–582.
[118]. Schaffer MR, Tantry U, Thornton FJ, Barbul A. Inhibition of nitric oxide synthesis in wounds:
Pharmacology and effect on accumulation of collagen in wounds in mice. Eur. J. Surg. 1999;
165:262–267. [PubMed: 10231662]
[119]. Shi HP, Efron DT, Most D, Tantry US, Barbul A. Supplemental dietary arginine enhances
wound healing in normal but not inducible nitric oxide synthase knockout mice. Surgery. 2000;
128:374–378. [PubMed: 10923019]
120. Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HDJ, Billiar TR.
Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol-Heart C.
1999; 277:1600–1608.
[121]. Schaffer MR, Tantry U, Gross SS, Wasserkrug HL, Barbul A. Nitric oxide regulates wound
healing. J. Surg. Res. 1996; 63:237–240. [PubMed: 8661204]
[122]. Stallmeyer B, Anhold M, Wetzler C, Kahlina K, Pfeilschifter J, Frank S. Regulation of eNOS in
normal and diabetes-impaired skin repair: Implications for tissue regeneration. Nitric Oxide-Biol.
Chem. 2002; 6:168–177.
[123]. Yamasaki K, Edington HDJ, McClosky C, Tzeng E, Lizonova A, Kovesdi I, Steed DL, Billiar
TR. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated
iNOS gene transfer. J. Clin. Invest. 1998; 101:967–971. [PubMed: 9486966]
[124]. Muscara MN, McKnight W, Asfaha S, Wallace JL. Wound collagen deposition in rats: effects
of an NO-NSAID and a selective COX-2 inhibitor. Br. J. Pharmacol. 2000; 129:681–686.
[PubMed: 10683192]
[125]. Thornton FJ, Schaffer MR, Witte MB, Moldawer LL, MacKay SLD, Abouhamze A, Tannahill
CL, Barbul A. Enhanced collagen accumulation following direct transfection of the inducible
nitric oxide synthase gene in cutaneous wounds. Biochem. Biophys. Res. Commun. 1998;
246:654–659. [PubMed: 9618268]
[126]. Shekhter AB, Serezhenkov VA, Rudenko TG, Pekshev AV, Vanin AF. Beneficial effect of
gaseous nitric oxide on the healing of skin wounds. Nitric Oxide-Biol. Chem. 2005; 12:210–219.
[127]. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-releasing
silica nanoparticles. Biomaterials. 2009; 30:2782–2789. [PubMed: 19233464]
Nichols et al. Page 20













[128]. Shabani M, Pulfer SK, Bulgrin JP, Smith DJ. Enhancement of wound repair with a topically
applied nitric oxide-releasing polymer. Wound Repair Regen. 1996; 4:353–362. [PubMed:
17177732]
[129]. Amadeu TP, Seabra AB, Oliveira MG, Costa AMA. S-nitrosoglutathione-containing hydrogel
accelerates rat cutaneous wound repair. Nitric Oxide-Biol. Chem. 2006; 14:A52–A52.
[130]. Amadeu TP, Seabra AB, de Oliveira MG, Monte-Alto-Costa A. Nitric oxide donor improves
healing if applied on inflammatory and proliferative phase. J. Surg. Res. 2008; 149:84–93.
[PubMed: 18374944]
[131]. Evers LH, Bhavsar D, Mailander P. The biology of burn injury. Exp. Dermatol. 2010; 19:777–
783. [PubMed: 20629737]
[132]. Becker WK, Shippee RL, McManus AT, Mason AD, Pruitt BA. Kinetics of nitrogen-oxide
production following experimental thermal-injury in rats. J. Trauma-Injury Infect. Crit. Care.
1993; 34:855–862.
[133]. Carter EA, Derojaswalker T, Tamir S, Tannenbaum SR, Yu YM, Tompkins RG. Nitric-oxide
production is intensely and persistently increased in tissue by thermal-injury. Biochem. J. 1994;
304:201–204. [PubMed: 7528006]
[134]. Paulsen SM, Wurster SH, Nanney LB. Expression of inducible nitric oxide synthase in human
burn wounds. Wound Repair Regen. 1998; 6:142–148. [PubMed: 9776857]
[135]. Akcay MN, Ozcan O, Gundogdu C, Akcay G, Balik A, Kose K, Oren D. Effect of nitric oxide
synthase inhibitor on experimentally induced burn wounds. J. Trauma-Injury Infect. Crit. Care.
2000; 49:327–330.
[136]. Inoue H, Ando K, Wakisaka N, Matsuzaki K, Aihara M, Kumagai N. Effects of nitric oxide
synthase inhibitors on vascular hyperpermeability with thermal injury in mice. Nitric Oxide-Biol.
Chem. 2001; 5:334–342.
[137]. Gibran NS, Boyce S, Greenhalgh DG. Cutaneous wound healing. J. Burn Care Res. 2007;
28:577–579. [PubMed: 17665518]
[138]. Zhu HF, Ka B, Murad F. Nitric oxide accelerates the recovery from burn wounds. World J.Surg.
2007; 31:624–631. [PubMed: 17308846]
[139]. Zhu HF, Wei XF, Bian K, Murad F. Effects of nitric oxide on skin burn wound healing. J. Burn
Care Res. 2008; 29:804–814. [PubMed: 18695618]
[140]. Schaffer MR, Tantry U, Efron PA, Ahrendt GM, Thornton FJ, Barbul A. Diabetes-impaired
healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation.
Surgery. 1997; 121:513–519. [PubMed: 9142149]
[141]. Le NN, Rose MB, Levinson H, Klitzman B. Implant healing in experimental animal models of
diabetes. J. Diabetes. Sci. Technol. 2011; 5:605–618. [PubMed: 21722576]
[142]. Schaffer M, Bongartz M, Fischer S, Proksch B, Viebahn R. Nitric oxide restores impaired
healing in normoglycaemic diabetic rats. J. Wound Care. 2007; 16:311–316. [PubMed:
17708383]
[143]. Witte MB, Kiyama T, Barbul A. Nitric oxide enhances experimental wound healing in diabetes.
Brit. J. Surg. 2002; 89:1594–1601. [PubMed: 12445072]
[144]. Singh RJ, Hogg N, Joseph J, Konorev E, Kalyanaraman B. The peroxynitrite generator, SIN-1,
becomes a nitric oxide donor in the presence of electron acceptors. Arch. Biochem. Biophys.
1999; 361:331–339. [PubMed: 9882464]
[145]. Weller R, Finnen MJ. The effects of topical treatment with acidified nitrite on wound healing in
normal and diabetic mice. Nitric Oxide-Biol. Chem. 2006; 15:395–399.
[146]. Mowbray M, Tan XJ, Wheatley PS, Morris RE, Weller RB. Topically applied nitric oxide
induces T-Lymphocyte infiltration in human skin, but minimal inflammation. J. Invest. Dermatol.
2008; 128:352–360. [PubMed: 17914444]
[147]. Dashti N, Einollahi N, Zarebavani M, Kiani F. The effect of DETA NONOate, a nitric oxide
donor, on the rate of collagen synthesis in rat as an animal model of diabetes. Int. J. Vet. Res.
2010; 4:159–161.
[148]. Li Y, Lee PI. Controlled Nitric Oxide Delivery Platform Based on S-Nitrosothiol Conjugated
Interpolymer Complexes for Diabetic Wound Healing. Mol. Pharmaceutics. 2010; 7:254–266.
Nichols et al. Page 21













[149]. Strachan CJL. The prevention of orthopedic implant vascular graft infections. J. Hosp. Infect.
1995; 30:54–63. [PubMed: 7560996]
[150]. O'Brien M. Functional anatomy and physiology of tendons. Clin. Sport. Med. 1992; 11:505–
520.
[151]. Andres BM, Murrell GAC. Treatment of tendinopathy: What works, what does not, and what is
on the horizon. Clin. Orthop. Rel. Res. 2008; 466:1539–1554.
[152]. Murrell GAC, Szabo C, Hannafin JA, Jang D, Dolan MM, Deng XH, Murrell DF, Warren RF.
Modulation of tendon healing by nitric oxide. Inflamm. Res. 1997; 46:19–27. [PubMed:
9117513]
[153]. Tomiosso TC, Nakagaki WR, Gomes L, Hyslop S, Pimentel ER. Organization of collagen
bundles during tendon healing in rats treated with L-NAME. Cell Tissue Res. 2009; 337:235–
242. [PubMed: 19506908]
[154]. Molloy TJ, de Bock CE, Wang Y, Murrell GAC. Gene expression changes in SNAP-stimulated
and iNOS-transfected tenocytes - Expression of extracellular matrix genes and its implications
for tendon-healing. J. Orthopaed. Res. 2006; 24:1869–1882.
[155]. Xia W, Szomor Z, Wang Y, Murrell GAC. Nitric oxide enhances collagen synthesis in cultured
human tendon cells. J. Orthopaed. Res. 2006; 24:159–172.
[156]. Xia W, Wang Y, Appleyard R, Smythe GA, Murrell GAC. Spontaneous recovery of injured
Achilles tendon in inducible nitric oxide synthase gene knockout mice. Inflamm. Res. 2006;
55:40–45. [PubMed: 16429255]
[157]. Lin J, Wang MX, Wei A, Zhu W, Murrell GAC. The cell specific temporal expression of nitric
oxide synthase isoforms during Achilles tendon healing. Inflamm. Res. 2001; 50:515–522.
[PubMed: 11713906]
[158]. Lin JH, Wang MX, Wei AQ, Zhu W, Diwan AD, Murrell GAC. Temporal expression of nitric
oxide synthase isoforms in healing Achilles tendon. J. Orthopaed. Res. 2001; 19:136–142.
[159]. Yuan J, Murrell GAC, Wei AQ, Appleyard RC, Del Soldato P, Wang MX. Addition of nitric
oxide via nitroflurbiprofen enhances the material properties of early healing of young rat Achilles
tendons. Inflamm. Res. 2003; 52:230–237. [PubMed: 12835894]
[160]. Murrell GAC, Tang GY, Appleyard RC, del Soldato P, Wang MX. Addition of nitric oxide
through nitric oxide-paracetamol enhances healing rat achilles tendon. Clin. Orthop. Rel. Res.
2008; 466:1618–1624.
[161]. Berrazueta JR, Losada A, Poveda J, Ochoteco A, Riestra A, Salas E, Amado JA. Successful
treatment of shoulder pain syndrome due to supraspinatus tendinitis with transdermal
nitroglycerin. A double blind study. Pain. 1996; 66:63–67. [PubMed: 8857632]
[162]. Paoloni JA, Appleyard RC, Nelson J, Murrell GAC. Topical nitric oxide application in the
treatment of chronic extensor tendinosis at the elbow - A randomized, double-blinded, placebo-
controlled clinical trial. Am. J. Sports Med. 2003; 31:915–920. [PubMed: 14623657]
[163]. Paoloni JA, Appleyard RC, Nelson J, Murrell GAC. Topical glyceryl trinitrate treatment of
chronic noninsertional achilles tendinopathy - A randomized, double-blind, placebo-controlled
trial. J. Bone. Joint. Surg. Am. 2004; 86A:916–922. [PubMed: 15118032]
[164]. Paoloni JA, Appleyard RC, Nelson J, Murrell GAC. Topical glyceryl trinitrate application in the
treatment of chronic supraspinatus tendinopathy - A randomized, double-blinded, placebo-
controlled clinical trial. Am. J. Sports Med. 2005; 33:806–813. [PubMed: 15827365]
[165]. Paoloni JA, Murrell GAC. Three-year followup study of topical glyceryl trinitrate treatment of
chronic noninsertional Achilles tendinopathy. Foot Ankle Int. 2007; 28:1064–1068. [PubMed:
17923056]
[166]. Kane TPC, Ismail M, Calder JDF. Topical glyceryl trinitrate and noninsertional Achilles
tendinopathy - A clinical and cellular investigation. Am. J. Sports Med. 2008; 36:1160–1163.
[PubMed: 18359821]
[167]. McCallum SDA, Paoloni JA, Murrell GAC. Five-year prospective comparison study of topical
glyceryl trinitrate treatment of chronic lateral epicondylosis at the elbow. Br. J. Sports Med.
2011; 45:416–420. [PubMed: 19553221]
Nichols et al. Page 22













[168]. Paoloni JA, Murrell GAC, Burch RM, Ang RY. Randomised, double-blind, placebo-controlled
clinical trial of a new topical glyceryl trinitrate patch for chronic lateral epicondylosis. Br. J.
Sports Med. 2009; 43:299–302. [PubMed: 18971247]
[169]. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA.
Mechanism of vascular smooth-muscle relaxation by organic nitrates, nitrites, nitroprusside and
nitric oxide - Evidence for the involvement of S-nitrosothols as active intermediates. J.
Pharmacol. Exp. Ther. 1981; 218:739–749. [PubMed: 6115052]
[170]. Park JW. Reaction of S-nitrosoglutathione with sulfhydryl-groups in protein. Biochem.
Biophys. Res. Commun. 1988; 152:916–920. [PubMed: 3284528]
[171]. Ewing JF, Young DV, Janero DR, Garvey DS, Grinnell TA. Nitrosylated bovine serum albumin
derivatives as pharmacologically active nitric oxide congeners. J. Pharmacol. Exp. Ther. 1997;
283:947–954. [PubMed: 9353418]
Nichols et al. Page 23














Primary NO-release mechanisms for three major classes of NO donors (N-
diazeniumdiolates, S-nitrosothiols, and organic nitrates).
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Structures of NO donors used to supply NO exogenously in biological studies.
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Nitric oxide-release half-lives from parent donor species predict release rate. Donor (b) has a
half-life 5 times greater than donor (a). Assuming first order kinetics and equal donor
concentrations, sustained NO-release durations will be longer for compound (b), but
maximum NO concentrations will be higher for compound (a).
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Structures of a clinical bisphosphonate, ibandronate, along with a nitrobisphosphonates
synthesized by Lazzarato et al. [83]. The bisphosphonate functionality along with the
hydroxyl group allow the bisphosphonate to bind effectively to bone while the organic
nitrate functionality confers NO release.
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External fixation pins coated with NO-releasing xerogels impart antimicrobial action to pin
surfaces, thus acting as a biocide against microbes that migrate into the pin tract.
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Release of NO from SIN-1, the hepatic product of molsidomine, occurs via this proposed
mechanism [144].
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Table 1
Nitric oxide release data from NO donors.
NO donor Donor type NO release half-life Experimental parameters Total NO (μmol mg−1)
PROLI/NO N-diazeniumdiolate 1.8 s [16] pH 7.4, 37 °C 7.97a
DETA/NO N-diazeniumdiolate 20 h [16] pH 7.4, 37 °C 12.25a
PAPA/NO N-diazeniumdiolate 15 min [16] pH 7.4, 37 °C 11.35a
CBC-NO N-diazeniumdiolate 31 minb [47] pH 7.4, 37 °C 0.05 [47]
PEIC-NO N-diazeniumdiolate 16 h [128] pH 7.4, 37 °C 0.0685 [128]
SNAP S-nitrosothiol 1.7 h [169] pH 7, 37 °C, 50 mM tris-HCl, 10 mM, in dark 4.54a
GSNO S-nitrosothiol 3 hc [170] pH 7.4, 37 °C, in dark 2.97a
SNO-BSA S-nitrosothiol 5 h [91] pH 7.4, 37 °C, 0.3 mM, in dark 0.227 [171]

























Theoretical total NO release based on chemical structure
b
Approximated by assuming first-order kinetics and 6 half-lives (95% decay)
c
Calculated from second order rate constant with 5 mM GSNO
d
Organic nitrates and metal nitrosyls do not spontaneously release NO at physiological pH and temperature
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